Impact of Natalizumab on Quality of Life in a Real-World Cohort of Patients With Multiple Sclerosis: Results From MS PATHS

Key Objectives
- Assess the impact of natalizumab on QoL via change in Quality of Life in Neurological Disorders (Neuro-QoL) scores
- Compare natalizumab with ocrelizumab to evaluate expectation bias

Eligible Patients
- Patients with any MS type who initiated natalizumab in MS PATHS

Neuro-QoL Tool
- Self-reported questionnaire
- 12 neurological domains related to physical, mental, and social health
- Previously validated in MS patients

Baseline Neuro-QoL impairment:
- T-score ≤45 for positively worded domains, OR
- T-score ≥55 for negatively worded domains

Study results suggest...
- Natalizumab has a positive impact on various aspects of physical, mental, cognitive, and emotional QoL in addition to its known effect on clinical and radiological outcomes
- QoL improvements with natalizumab are not likely driven by expectation bias, as the magnitude of improvements was greater than with ocrelizumab

1. Improvement was seen in the overall natalizumab treatment population

   Neuro-QoL domains with significant* improvement in 164 patients analyzed

2. Clinically meaningful improvement with natalizumab was observed using 2 different assessments

   Neuro-QoL domains with significant* improvement in patients with baseline impairment

3. Natalizumab-associated QoL improvements are not driven primarily by expectation bias based on comparison with patients treated with a different high-efficacy therapy

   (comparison based on propensity score weighting and adjustment for relevant co-medications, year, and drug-year interaction)

   Participation in social roles and activities
   Satisfaction with social roles and activities
   Emotional and behavioral dyscontrol

   Neuro-QoL domains

   Positively worded Neuro-QoL domains

   Negatively worded Neuro-QoL domains

   ↑ improvement with natalizumab vs ocrelizumab (p=0.0001)

   ↑ improvement with natalizumab vs ocrelizumab (p=0.02)

   ↑ improvement with natalizumab vs ocrelizumab (p=0.01)

   "n"=144

   "n"=502

* p≤0.05